NDX-3315
- Generic Name
- NDX-3315
- Drug Type
- Small Molecule
- Background
NDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled heparin.
A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- NexEos Diagnostics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05757856
- Locations
- 🇺🇸
Northwestern Univerisity, Chicago, Illinois, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath